前列腺癌患者转移灶定向治疗的疗效与安全性:前瞻性研究的系统评价与Meta分析
该系统评价与Meta分析纳入22项前瞻性研究(n=1137),评估转移灶定向治疗(MDT)在转移性前列腺癌患者中的肿瘤学与安全性结局。估计2年无进展生存率为46%(95%CI:36-56%),2年局部控制率、无雄激素剥夺治疗生存率和总生存率分别为97%、55%和97%,治疗相关2级和≥3级不良事件发生率分别为2.4%和0.3%。作者认为MDT是有前景的治疗策略,但在缺乏随机试验的情况下,用于治疗强化仍属实验性方法,对总生存的影响不确定。
要点
- MDT与有利的无进展生存、极佳的局部控制和低毒性相关。
- 寡复发激素敏感患者可通过MDT避免或推迟ADT相关毒性。
- 缺乏随机试验时,MDT用于治疗强化仍属实验性方法,对OS影响不确定。
核心结论
- MDT是有前景的治疗策略,与有利的PFS、极佳的LC和低毒性特征相关,使寡复发激素敏感患者能够避免或推迟ADT相关毒性。
- 将MDT与其他治疗整合提供了有前景的研究方向,特别是与全身治疗联合以及作为寡转移性前列腺癌根治性治疗的组成部分。
- 在缺乏随机试验的情况下,使用MDT进行治疗强化仍属实验性方法,对OS的影响不确定。
研究设计与样本
- 检索PubMed、Scopus和Web of Science数据库,纳入评估MDT治疗转移性前列腺癌患者PFS、LC、ADT-FS、OS和/或AEs的前瞻性研究。
- 共纳入22项前瞻性研究(n=1137),包括两项随机对照试验(n=116)。
- 两项研究(n=120)被排除在Meta分析之外。
- 对1年和2年PFS、LC、ADT-FS、OS及AEs发生率进行Meta分析,并进行Meta回归和敏感性分析以处理异质性并识别调节因素。
主要发现
- 估计2年PFS为46%(95%CI:36-56%),排除使用生化或ADT相关终点的研究后为42%(95%CI:33-52%)。
- 估计2年LC为97%(95%CI:94-98%),2年ADT-FS为55%(95%CI:44-65%),2年OS为97%(95%CI:95-98%)。
- 治疗相关2级AEs发生率为2.4%(95%CI:0.2-7%),≥3级AEs发生率为0.3%(95%CI:0-1%)。
临床怎么用
- MDT是经过选择的前列腺癌患者的有前景选择,可推迟激素治疗,并正被研究作为以可控毒性为代价强化治疗的方式。
局限性
- 缺乏随机试验,使用MDT进行治疗强化仍属实验性方法,对OS的影响不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite the lack of level 1 evidence, metastasis-directed therapy (MDT) is used widely in the management of metastatic prostate cancer (mPCa) patients. Data are continuously emerging from well-designed prospective studies. OBJECTIVE: To summarise and report the evidence on oncological and safety outcomes of MDT in the management of mPCa patients. EVIDENCE ACQUISITION: We searched the PubMed, Scopus, and Web of Science databases for prospective studies assessing progression-free survival (PFS), local control (LC), androgen deprivation therapy (ADT)-free survival (ADT-FS), overall survival (OS), and/or adverse events (AEs) in mPCa patients treated with MDT. A meta-analysis was performed for 1- and 2-yr PFS, LC, ADT-FS, OS, and rate of AEs. Meta-regression and sensitivity analysis were performed to account for heterogeneity and identify moderators. EVIDENCE SYNTHESIS: We identified 22 prospective studies (n = 1137), including two randomised controlled trials (n = 116). Two studies were excluded from the meta-analysis (n = 120). The estimated 2-yr PFS was 46% (95% confidence interval [CI]: 36-56%) or 42% (95% CI: 33-52%) after excluding studies using biochemical or ADT-related endpoints. The estimated 2-yr LC, ADT-FS, and OS were 97% (95% CI: 94-98%), 55% (95% CI: 44-65%), and 97% (95% CI: 95-98%), respectively. Rates of treatment-related grade 2 and ≥3 AEs were 2.4% (95% CI: 0.2-7%) and 0.3% (95% CI: 0-1%), respectively. CONCLUSIONS: MDT is a promising treatment strategy associated with favourable PFS, excellent LC, and a low toxicity profile that allows oligorecurrent hormone-sensitive patients to avoid or defer ADT-related toxicity. Integration of MDT with other therapies offers a promising research direction, in particular, in conjunction with systemic treatments and as a component of definitive care for oligometastatic PCa. However, in the absence of randomised trials, using MDT for treatment intensification remains an experimental approach, and the impact on OS is uncertain. PATIENT SUMMARY: Direct treatment of metastases is a promising option for selected prostate cancer patients. It can delay hormone therapy and is being investigated as a way of intensifying treatment at the expense of manageable toxicity.
引用
- Miszczyk M, Rajwa P, Yanagisawa T, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. 2023. PMID: 37945451. doi:10.1016/j.eururo.2023.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。